Organogenesis Hldgs (NASDAQ: ORGO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.050 | 0.010 | -0.0400 | ||||
REV | 95.930M | 98.117M | 2.187M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Organogenesis Hldgs (NASDAQ: ORGO) through any online brokerage.
Other companies in Organogenesis Hldgs’s space includes: Avidity Biosciences (NASDAQ:RNA), Cogent Biosciences (NASDAQ:COGT), TG Therapeutics (NASDAQ:TGTX), Sangamo Therapeutics (NASDAQ:SGMO) and AnaptysBio (NASDAQ:ANAB).
The latest price target for Organogenesis Hldgs (NASDAQ: ORGO) was reported by SVB Leerink on Wednesday, November 10, 2021. The analyst firm set a price target for 20.00 expecting ORGO to rise to within 12 months (a possible 300.00% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Organogenesis Hldgs (NASDAQ: ORGO) is $5 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Organogenesis Hldgs.
Organogenesis Hldgs’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Organogenesis Hldgs.
Organogenesis Hldgs is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.